Our Science – Dahut Website
William L. Dahut, M.D.
Selected Publications |
 |
| 1)
Dahut WL, Madan RA, Karakunnel JJ, Adelberg D, Gulley JL, Turkbey IB, Chau CH, Spencer SD, Mulquin M, Wright J, Parnes HL, Steinberg SM, Choyke PL, Figg WD. Phase II clinical trial of cediranib in patients with metastatic castration-resistant prostate cancer. BJU Int. [Epub ahead of print], 2013. [Journal] |
|
| 2)
Madan RA, Mohebtash M, Arlen PM, Vergati M, Rauckhorst M, Steinberg SM, Tsang KY, Poole DJ, Parnes HL, Wright JJ, Dahut WL, Schlom J, Gulley JL. Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial. Lancet Oncol. 13: 501-8, 2012. [Journal] |
|
| 3)
Kamrava M, Kesarwala AH, Madan RA, Lita E, Kaushal A, Tsang K, Poole DJ, Steinberg SM, Ferrara T, Dahut W, Schlom J, Gulley JL. Long-term follow-up of prostate cancer patients treated with vaccine and definitive radiation therapy. Prostate Cancer Prostatic Dis. [Epub ahead of print], 2012. [Journal] |
|
| 4)
Gulley JL, Leitman SF, Dahut W, Schlom J. Re: interdisciplinary critique of sipuleucel-T as immunotherapy in castration-resistant prostate cancer. J. Natl. Cancer Inst. 104: 1106; author reply 1109-12, 2012. [Journal] |
|
| 5)
Peer CJ, Sissung TM, Kim A, Jain L, Woo S, Gardner ER, Kirkland CT, Troutman SM, English BC, Richardson ED, Federspiel J, Venzon D, Dahut W, Kohn E, Kummar S, Yarchoan R, Giaccone G, Widemann B, Figg WD. Sorafenib is an inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic variants on pharmacokinetics and hyperbilirubinemia. Clin. Cancer Res. 18: 2099-107, 2012. [Journal] |
|
| 6)
Kurdziel KA, Shih JH, Apolo AB, Lindenberg L, Mena E, McKinney YY, Adler SS, Turkbey B, Dahut W, Gulley JL, Madan RA, Landgren O, Choyke PL. The Kinetics and Reproducibility of 18F-Sodium Fluoride for Oncology Using Current PET Camera Technology. J. Nucl. Med. 53: 1175-84, 2012. [Journal] |
|
| 7)
Mohebtash M, Tsang KY, Madan RA, Huen NY, Poole DJ, Jochems C, Jones J, Ferrara T, Heery CR, Arlen PM, Steinberg SM, Pazdur M, Rauckhorst M, Jones EC, Dahut WL, Schlom J, Gulley JL. A pilot study of MUC-1/CEA/TRICOM poxviral-based vaccine in patients with metastatic breast and ovarian cancer. Clin. Cancer Res. 17: 7164-73, 2011. [Journal] |
|
| 8)
Bilusic M, Dahut WL. Cabazitaxel: a new drug for metastatic prostate cancer. Asian J. Androl. 13: 185-6, 2011. [Journal] |
|
| 9)
Madan RA, Aragon-Ching JB, Gulley JL, Dahut WL. From clinical trials to clinical practice: therapeutic cancer vaccines for the treatment of prostate cancer. Expert Rev Vaccines. 10: 743-53, 2011. [Journal] |
|
| 10)
Tanno T, Rabel A, Alleyne M, Lee YT, Dahut WL, Gulley JL, Miller JL. Hepcidin, anaemia, and prostate cancer. BJU Int. 107: 678-9, 2011. [Journal] |
|
| Click Here to View Expanded Bibliography. |
This page was last updated on 4/9/2013.
